Drug insight: Clopidogrel nonresponsiveness (Q28198683)

Nature Clinical Practice Cardiovascular Medicine

Europe PubMed Central

title

Drug insight: Clopidogrel nonresponsiveness (English)

0 references

1 reference

1

Paul A Gurbel

0 references

author name string

Udaya S Tantry

series ordinal

2

0 references

language of work or name

English

0 references

publication date

July 2006

0 references

published in

0 references

volume

3

0 references

issue

7

0 references

page(s)

387-95

0 references

cites work

Platelet activation in myocardial ischemic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Resistance to antiplatelet drugs: current status and future research

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Central role of the P2Y12 receptor in platelet activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet, Not Endothelial, P-Selectin Is Required for Neointimal Formation After Vascular Injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Individual variations of platelet inhibition after loading doses of clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Variability in platelet responsiveness to clopidogrel among 544 individuals.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Pharmacokinetics of clopidogrel after administration of a high loading dose

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet activation in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

The difference between clopidogrel responsiveness and posttreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0602

7 January 2021